Rheos Medicines CSO Dania Rabah to Deliver Keynote Address at AAPS National Biotechnology Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Rheos Medicines, Inc., a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and inflammatory diseases, announced that Dania Rabah, PhD, the company’s Chief Scientific Officer, will deliver a keynote address today at the American Association for Pharmaceutical Scientists (AAPS) National Biotechnology Conference being held this week in Anaheim, CA. The keynote presentation is entitled “A New Era of Precision Medicine for Autoimmune and Inflammatory Diseases” and is featured as part of the conference’s session on new modalities in drug innovation.

“Autoimmune and inflammatory diseases are a highly heterogeneous group of diseases that affect millions of patients. Emerging drug development approaches are opening up more precise, molecularly-targeted ways to address the vast unmet needs of these patients,” said Dr. Rabah. “Rheos is proud to be a pioneer in bringing molecularly targeted medicines to patient subpopulations with these complex immune-mediated diseases.”

Keynote Address: A New Era of Precision Medicine for Autoimmune and Inflammatory Diseases
Date: May 12, 2022
Time: 1:00-2:00 p.m. PT
Conference: AAPS National Biotechnology Conference, Anaheim, CA, May 9-12, 2022

In this presentation, Dr. Rabah will describe how Rheos’s approach to precision medicine can create more effective therapeutics for autoimmune and inflammatory diseases. Rheos has built a proprietary MetPM™ platform that is based on a comprehensive understanding of the cellular metabolism of the immune system. This platform enables the discovery of precision medicines that target the fundamental underpinnings of the immune system dysfunction while, at the same time, identifying the molecular signatures that define distinct patient subsets.

About Rheos Medicines

Rheos Medicines is a biopharmaceutical company developing precision medicines to treat autoimmune and inflammatory diseases by identifying and targeting the molecular characteristics and patient subsets for these complex diseases. Using our proprietary MetPM™ platform, the Rheos team integrates an unmatched knowledge base of immunometabolism networks based on bioinformatic integration of genetic, transcriptomic, epigenomic and metabolomic datasets, including from patient data and samples. We have built a pipeline of novel, differentiated drug programs to address autoimmune and inflammatory diseases by targeting fundamental underpinnings of immune system dysfunction while, at the same time, identifying the molecular signatures for patient stratification and selection. Rheos has assembled leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team. Rheos was founded by Third Rock Ventures and is located in Cambridge, MA. For more information, please visit www.rheosrx.com/. We invite you to follow us on LinkedIn and @Rheosrx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005221/en/